Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, comprising approximately 75% of all kidney tumors. Recent the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) studies have significantly advanced the molecular characterization of RCC and facilitated the development of targeted therapies. Such advances have improved the median survival of patients with advanced disease from less than 10 months prior to 2004 to 30 months by 2011. However, approximately 30% of localized ccRCC patients will nevertheless develop recurrence or metastasis after surgical resection of their tumor. Therefore, it is critical to further analyze potential tumor-associated proteins and their profiles during disease progression. Over the past decade, tremendous effort has been focused on the study of molecular pathways, including genomics, transcriptomics, and proteomics in order to identify potential molecular biomarkers, as well as to facilitate early detection, monitor tumor progression and uncover potentially therapeutic targets. In this review, we focus on recent advances in the proteomic analysis of ccRCC, current strategies and challenges, and perspectives in the field. This insight will highlight the discovery of tumor-associated proteins, and their potential clinical impact on personalized precision-based care in ccRCC.
Seminars in cancer biology. 2018 Jul 25 [Epub ahead of print]
Qing Kay Li, Christian P Pavlovich, Hui Zhang, Christopher R Kinsinger, Daniel W Chan
Department of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, United States. Electronic address: ., Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, United States., Department of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, United States., Clinical Proteomic Tumor Analysis Consortium, NCI/NIH, Bethesda, MD, 20892, United States.